NCT02467387View on ClinicalTrials.gov

A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 1, 2014

Primary Completion Date

May 11, 2017

Study Completion Date

May 11, 2017

Conditions
Non-Ischemic Heart Failure
Interventions
DRUG

Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)

One time infusion Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg.

DRUG

Lactated Ringer's Solution

One time infusion 1.5mL/kg

Trial Locations (5)

11794

Stony Brook Heart Institute, Stony Brook

19104

Hospital of the University of Pennsylvania, Heart Failure and Transplant Program, Philadelphia

20010

MedStar Washington Hospital Center, Washington D.C.

30322

Emory University Hospital, Atlanta

60611

Northwestern University Centers for Heart Failure Therapy, Chicago

Sponsors

Lead Sponsor

CardioCell LLC
All Listed Sponsors
collaborator

Stemedica Cell Technologies, Inc.

INDUSTRY

lead

CardioCell LLC

INDUSTRY

NCT02467387 - A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure | Biotech Hunter | Biotech Hunter